imetelstat sodium

Phase 2Small molecule

GGeron Corporation

imetelstat sodium is one of 205 small molecule programs targeting Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

204

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

MyelofibrosisActive, not recruiting

Myelodysplastic SyndromeActive, not recruiting

Breast CancerActive, not recruiting

Multiple MyelomaActive, not recruiting

Small Cell Lung CancerActive, not recruiting

LymphomaPhase 1

Active, not recruiting

MyelofibrosisPhase 1

Active, not recruiting

Myelodysplastic SyndromePhase 2/Phase 3

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Multiple MyelomaPhase 1

Active, not recruiting

Small Cell Lung CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Preclinical

36 2

imetelstat sodium

GGeron Corporation

Phase 2

1 3

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 4

DATROWAY

Daiichi Sankyo

Preclinical

4 5

Megace

Bristol-Myers Squibb

Preclinical

4 6

Lexiscan

Astellas

Preclinical

1 7

Lupron

EEastern Cooperative Oncology Group

Preclinical

5 8

Tricor

JJagotec

Preclinical

1 9

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 10

Zoladex

Luye Pharma Group Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2/3Active, not recruiting

Myelodysplastic Syndrome

NCT02598661

Q3 2028

Phase 1Recruiting

Myelofibrosis

NCT05371964

Clinical

Trials by Indication[1]

Lymphoma1 trial

Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma

Completed·CChildren's Oncology Group·Phase 1·NCT01273090·34 enrolled

Myelofibrosis1 trial

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis

Recruiting·GGeron Corporation·Phase 1·NCT05371964·36 enrolled

Refractory Solid Tumors1 trial

Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Withdrawn·CChildren's Oncology Group·Phase 2·NCT02011126

Breast Cancer1 trial

Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer

Completed·GGeron Corporation·Phase 2·NCT01256762·166 enrolled

Small Cell Lung Cancer1 trial

Study of GRN163L With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non Small Cell Lung Cancer

Completed·GGeron Corporation·Phase 1·NCT00510445·27 enrolled

6 more indications

Multiple Myeloma1 trial

Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma

Completed·GGeron Corporation·Phase 1·NCT00594126·20 enrolled

Solid Tumor Malignancies1 trial

Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies

Completed·GGeron Corporation·Phase 1·NCT00310895·85 enrolled

Refractory1 trial

Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma

Completed·GGeron Corporation·Phase 1·NCT00718601·40 enrolled

Recurrent or Refractory1 trial

Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors

Terminated·PPediatric Brain Tumor Consortium·Phase 2·NCT01836549·43 enrolled

Imetelstat1 trial

Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy

Active, not recruiting·GGCP-Service International West GmbH·Phase 2·NCT05583552·46 enrolled

Myelodysplastic Syndrome1 trial

Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Active, not recruiting·GGeron Corporation·Phase 2/3·NCT02598661·289 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for imetelstat sodium. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — imetelstat sodium compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for imetelstat sodium. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Geron Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GGeron Corporation

imetelstat sodium

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2028

Trials by Indication[1]

Lymphoma1 trial

Myelofibrosis1 trial

Refractory Solid Tumors1 trial

Breast Cancer1 trial

Small Cell Lung Cancer1 trial

Multiple Myeloma1 trial

Solid Tumor Malignancies1 trial

Refractory1 trial

Recurrent or Refractory1 trial

Imetelstat1 trial

Myelodysplastic Syndrome1 trial

References

Drug Info

Quick Facts

Related News